Embargo: 3 June 2026 at 16:00 UK / 11:00 US ET Time
Peer-reviewed / IBD / Patient data
STUDY OF MILLIONS OF CELLS REVEALS NEW WAY TO UNDERSTAND GENETIC RISK OF DISEASE
Scientists have created the most detailed cell map to date showing how genetic variation influences inflammatory bowel disease (IBD), revealing the specific cells and genes that drive the disease.
Published today (3 June) in Nature , the research carried out at the Wellcome Sanger Institute, Open Targets, and Cambridge University Hospitals NHS Foundation Trust (CUH), identifies the key genetic and cellular drivers of IBD risk and demonstrates the power of single-cell approaches to understand the complex nature of human disease.
The findings lay the foundation for the development and repurposing of new treatments across many diseases.
IBD – which includes Crohn’s disease and ulcerative colitis – is characterised by chronic inflammation of the gastrointestinal tract and affects over 4.9 million people worldwide, 1 including more than half a million in the UK. 2
Inherited changes in DNA are known to play a major role in determining whether someone may be susceptible to IBD. However, translating this knowledge into biological understanding is difficult because over 90 per cent of DNA changes linked to IBD lie outside regions of the genome that code for proteins. These DNA changes are therefore thought to influence the disease by altering how strongly particular genes are switched on or off, known as the gene ‘expression’ level.
However, identifying the specific genes and cell types dysregulated by these DNA changes have proven difficult. This is because most cellular studies of disease analyse whole tissue samples that blend many cell types together, masking effects that only operate in specific cells.
In a new study, researchers at the Sanger Institute, Open Targets, CUH and their collaborators sought to understand whether studying the expression level of genes in individual cell types could better explain how genetic risk contributes to IBD.
The team collected blood and gut samples at Addenbrooke’s Hospital in Cambridge, UK from just over 400 individuals, including 125 people with Crohn’s disease. 3 Gut samples were collected from the terminal ileum – the last portion of the small intestine – and the rectum. The terminal ileum and rectum are the most commonly affected sites in Crohn’s disease and ulcerative colitis, respectively.
The researchers generated 'IBDverse', the largest single-cell dataset from gut tissue and blood from Crohn’s disease and healthy patients, containing gene expression data from roughly 2.2 million individual cells. They measured the expression level of tens of thousands of genes in each of these cells using a method called single-cell RNA sequencing. They then linked inherited genetic differences to changes in gene expression level and compared these to known genetic risk regions for IBD.
Many genetic effects linked to IBD were found to only appear in specific cell types and are missed when studying whole tissues. The team identified likely effector genes – genes that are most likely to drive disease – at more than half of known genetic regions associated with IBD.
The researchers found that many genetic effects occurred in immune cells, particularly in dendritic cells, 4 which resulted in reduced Notch signalling – a pathway involved in regulating immune responses in the gut.
They also identified genetic effects in a type of cell that covers the body's internal and external surfaces, known as epithelial cells. These genetic changes dysregulated the expression of Wnt-regulated genes which control crucial cellular functions. 5 This leads to reduced tissue renewal that may weaken the gut lining and contribute to IBD susceptibility.
Overall, the study demonstrates the power of single-cell sequencing and genetics to unlock the mysteries of disease. The findings suggest that IBD arises from a combination of immune system dysregulation and failure of the gut lining to repair itself properly.
The study also points to broader implications for drug development. Among the genes identified, the researchers found a potential explanation for why metformin – one of the most widely prescribed drugs for type 2 diabetes – commonly causes gastrointestinal side effects, suggesting that single-cell genetic mapping could help anticipate the tissue-specific effects of existing drugs. Beyond IBD, the findings demonstrate a broadly applicable framework for connecting genetic risk to specific cells and pathways in any disease where relevant tissue can be sampled, with potential applications for conditions including asthma, psoriasis and endometriosis.
Dr Bradley Harris, co-first author at the Wellcome Sanger Institute, said: “To our surprise, many of the newly nominated effector genes regulate pathways that were previously underappreciated in the context of IBD risk. These associations also accumulated in specific cell types of the gut, such as dendritic cells and gut stem cells, which are not commonly associated with the disease. This work therefore really helps us understand the overall picture of what molecular changes cause IBD, and in which cell types and tissues.”
Dr Alan Moss, MD, Chief Scientific Officer of the Crohn’s & Colitis Foundation, one of the study’s funders, said: “The Foundation is pleased to support this important project as part of its genetics initiative. This high-resolution cell map provides more granular information on which pathways are abnormal in different cell types in IBD. Information such as this can guide researchers to disease signals in specific cell types. These data can reveal new mechanisms of disease, and potentially more targeted treatments for patients.”
Dr Tim Raine, co-senior author and consultant gastroenterologist at CUH, said: “When we started planning this study, single-cell sequencing projects typically involved tens of individuals. We knew that to have any real power to answer these questions, we would need to obtain tissue samples at a far larger scale, involving hundreds of patients undergoing invasive biopsies specifically for this research. The willingness of those patients to contribute, and the extraordinary effort of the clinical and laboratory teams to collect and process samples at that scale, made this unprecedented science possible.”
Dr Carl Anderson, co-senior author at the Wellcome Sanger Institute and Open Targets, said: “Genome-wide association studies have told us where in the genome IBD risk resides, but this study tells us which genes these risk variants disrupt and in which cell types this occurs. What’s really exciting about this, in addition to the many lessons we’ve learned about IBD biology, is that the same approach can be used to unlock the biological mysteries of many different diseases. Single-cell sequencing at scale provides a high-resolution view of disease biology, and by combining that with genetic variation, we can now make the insights needed to drive better drug target identification.”
ENDS
Contact details:
Susannah Young
Press Office
Wellcome Sanger Institute
Cambridge, CB10 1SA
Email: press.office@sanger.ac.uk
Mobile: +44 (0)7907391759
Notes to Editors:
T. Vos et al . (2020) 'Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.' Lancet. DOI: 10.1016/S0140-6736(20)30925-9.
Crohn’s & Colitis UK (2022). ‘New research shows over 1 in 123 people in UK living with Crohn’s or Colitis .’ Available at: https://crohnsandcolitis.org.uk/news-stories/news-items/new-research-shows-over-1-in-123-people-in-uk-living-with-crohn-s-or-colitis [74n5c4m7.r.eu-west-1.awstrack.me] [Last accessed: May 2026]
296 individuals without IBD and 125 with Crohn’s disease were recruited at Addenbrooke’s Hospital, Cambridge, UK. During routine endoscopy, gastrointestinal biopsies were collected from the rectum and terminal ileum, and blood samples were drawn after the procedure. Terminal ileal biopsies were obtained from 243 individuals without IBD and 119 individuals with Crohn’s disease. Rectal biopsies were collected from 275 individuals without IBD. Whole blood was collected from 95 individuals with Crohn’s disease.
Dendritic cells are a specialised subset of immune cells that develop in the bone marrow. They patrol cells, capture pathogens and present antigens to T cells to initiate immune responses.
The Wnt-signalling pathways are a group of signalling pathways that begin with proteins that pass signals into a cell through cell surface receptors. The process regulates fundamental biological processes, including cell fate determination, proliferation and migration.
Publication:
T. Alegbe et al. (2026) ‘Cell-type-resolved genetic regulatory variation shapes inflammatory bowel disease risk’. Nature DOI: 10.1038/s41586-026-10627-z
Funding:
This research was supported in part by the NIHR Cambridge Biomedical Research Centre, Wellcome, The Crohn’s & Colitis Foundation Genetics Initiative and Open Targets.
Selected websites:
Open Targets
Open Targets is a pre-competitive, public-private partnership that uses human genetics and genomics data to systematically identify and prioritise drug targets. Through large-scale genomic experiments and the development of innovative computational techniques, the partnership aims to help researchers select the best targets for the development of new therapies.
Founded in 2014, Open Targets brings together the world-class expertise of EMBL’s European Bioinformatics Institute and the Wellcome Sanger Institute with the drug discovery capabilities of leading industry partners, currently GSK, Genentech, MSD, Sanofi, and Pfizer. The consortium also collaborates globally to engage with expertise and capabilities aligned with its mission.
https://www.opentargets.org [74n5c4m7.r.eu-west-1.awstrack.me]
About Cambridge University Hospitals
Cambridge University Hospitals NHS Foundation Trust (CUH) is one of the largest and best known trusts in the country, delivering high-quality patient care through Addenbrooke’s and the Rosie Hospitals. CUH is a leading national centre for specialist treatment for rare or complex conditions and a university teaching hospital with a worldwide reputation.
CUH is a key partner in Cambridge University Health Partners (CUHP), one of only eight academic health science centres in the UK and is at the heart of the development of the Cambridge Biomedical Campus (CBC), which brings together on one site a range of organisations involved in world-class biomedical research, patient care and education. The Campus hosts the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre.
www.facebook.com/CambridgeUniversityHospitals [74n5c4m7.r.eu-west-1.awstrack.me]
www.twitter.com/CUH_NHS [74n5c4m7.r.eu-west-1.awstrack.me]
For more about Cambridge University Hospitals (CUH) visit: http://www.cuh.org.uk/ [74n5c4m7.r.eu-west-1.awstrack.me]
The Wellcome Sanger Institute
The Wellcome Sanger Institute is a world leader in genomics research. We apply and explore genomic technologies at scale to advance understanding of biology and improve health. Making discoveries not easily made elsewhere, our research delivers insights across health, disease, evolution and pathogen biology. We are open and collaborative; our data, results, tools, technologies and training are freely shared across the globe to advance science.
Funded by Wellcome, we have the freedom to think long-term and push the boundaries of genomics. We take on the challenges of applying our research to the real world, where we aim to bring benefit to people and society.
Find out more at www.sanger.ac.uk [74n5c4m7.r.eu-west-1.awstrack.me] or follow us on Twitter [74n5c4m7.r.eu-west-1.awstrack.me] , Instagram, Facebook [74n5c4m7.r.eu-west-1.awstrack.me] , LinkedIn [74n5c4m7.r.eu-west-1.awstrack.me] and on our Blog [74n5c4m7.r.eu-west-1.awstrack.me] .
About Wellcome
Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, infectious disease and climate and health. https://wellcome.org/ [74n5c4m7.r.eu-west-1.awstrack.me]
Nature
Cell-type-resolved genetic regulatory variation shapes inflammatory bowel disease risk’
3-Jun-2026